Medien
BASF introduces Kollicoat® MAE 100-55 – a new opportunity for the formulation of pharmaceutical enteric film coatings
- Kollicoat® MAE 100-55 will be introduced at PBP World Meeting in Glasgow
- Enabling direct substitution in commercial enteric pharmaceutical formulations
- Easier handling due to dust free material
Glasgow, United Kingdom – April 4, 2016 – BASF is introducing Kollicoat® MAE 100-55 at the 10th World Meeting on Pharmaceutics, Biopharmaceuticals and Pharmaceutical Technology (PBP) in Glasgow, United Kingdom, from April 4 – 7, 2016.
Kollicoat® MAE 100-55 is the latest addition in BASF’s comprehensive portfolio of functional excipients for Instant & Modified Release. As a new reliable source for this type of coating polymer, Kollicoat® MAE 100-55 can directly replace comparable pH >5.5 enteric release materials in commercial formulations. As it matches the release profile and complies with applicable regulatory monographs, Kollicoat® MAE 100-55 can be used today without re-registration.
Moreover, the superior size of the dried powder particles delivers dust free handling, thus making operations easy, efficient and clean. Beyond its advantages in handling, Kollicoat® MAE 100-55 provides equivalent drug release as existing comparable products in the market.
“Kollicoat® MAE 100-55 extends our offer of pH >5.5 enteric release coatings based on methacrylic acid-ethylacrylate copolymer, providing pharmaceutical manufacturers more flexibility and supply security,” says Kai Sievert, Head of Global Marketing Pharma Solutions at BASF.
With its expertise in polymer chemistry, its research & development capabilities around the globe and the company’s clear commitment to developing pharmaceutical excipients, BASF continuously creates solutions to overcome formulation challenges related to Instant & Modified Release, Solubilization, Softgels and Skin Delivery.
- Visit BASF at the PBP: Booth No. 16/11
- Watch the video on the dust free performance of Kollicoat® MAE 100-55: https://youtu.be/KrB1Q23rcfg
- For more information visit: www.pharma.basf.com
- Follow us on Twitter: @BASF_Pharma
About the BASF Nutrition & Health division
BASF Nutrition & Health provides a comprehensive product and service portfolio for the human and animal nutrition, pharmaceutical and flavor & fragrance industries. With innovative solutions and modern technologies we help our customers improve their business efficiency and the sustainability of their products. Our human nutrition solutions include vitamins and carotenoids, plant sterols, emulsifiers and omega-3 fatty acids. Vitamins and carotenoids also form an important part of our animal nutrition portfolio, as do other feed additives such as trace elements, enzymes and organic acids. We provide the pharmaceutical industry with a broad range of excipients and selected large-volume active pharmaceutical ingredients such as ibuprofen and omega-3 fatty acids. Furthermore, we offer aroma ingredients such as citral, geraniol and L-menthol. BASF Nutrition & Health operates sites in Europe, North America, South America and in Asia-Pacific. For more information, go to www.basf.com.
About BASF
At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. The approximately 112,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into five segments: Chemicals, Performance Products, Functional Materials & Solutions, Agricultural Solutions and Oil & Gas. BASF generated sales of more than €70 billion in 2015. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information at www.basf.com.
P-16-164
